As of 2025-07-16, the Intrinsic Value of Aurobindo Pharma Ltd (AUROPHARMA.NS) is 642.02 INR. This AUROPHARMA.NS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 1,152.00 INR, the upside of Aurobindo Pharma Ltd is -44.30%.
The range of the Intrinsic Value is 554.00 - 772.70 INR
Based on its market price of 1,152.00 INR and our intrinsic valuation, Aurobindo Pharma Ltd (AUROPHARMA.NS) is overvalued by 44.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 554.00 - 772.70 | 642.02 | -44.3% |
| DCF (Growth 10y) | 626.76 - 839.40 | 713.41 | -38.1% |
| DCF (EBITDA 5y) | 1,314.95 - 1,936.42 | 1,583.99 | 37.5% |
| DCF (EBITDA 10y) | 1,197.21 - 1,797.61 | 1,452.92 | 26.1% |
| Fair Value | 1,013.25 - 1,013.25 | 1,013.25 | -12.04% |
| P/E | 1,517.14 - 2,172.67 | 1,606.71 | 39.5% |
| EV/EBITDA | 1,358.38 - 2,074.30 | 1,734.03 | 50.5% |
| EPV | 553.01 - 646.73 | 599.87 | -47.9% |
| DDM - Stable | 317.06 - 589.31 | 453.18 | -60.7% |
| DDM - Multi | 374.44 - 544.88 | 444.18 | -61.4% |
| Market Cap (mil) | 669,081.60 |
| Beta | 0.99 |
| Outstanding shares (mil) | 580.80 |
| Enterprise Value (mil) | 669,355.40 |
| Market risk premium | 8.31% |
| Cost of Equity | 14.21% |
| Cost of Debt | 6.06% |
| WACC | 13.30% |